WO2012128582A3 - Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant - Google Patents

Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant Download PDF

Info

Publication number
WO2012128582A3
WO2012128582A3 PCT/KR2012/002100 KR2012002100W WO2012128582A3 WO 2012128582 A3 WO2012128582 A3 WO 2012128582A3 KR 2012002100 W KR2012002100 W KR 2012002100W WO 2012128582 A3 WO2012128582 A3 WO 2012128582A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
same
compound
dehydrogenase type
steroid dehydrogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/002100
Other languages
English (en)
Other versions
WO2012128582A2 (fr
Inventor
In Hee Lee
Chang Min Park
Se Hoan Kim
Hee Il Chae
Doo Hyeok PYEON
Myoung Hyeon SHIN
Jeong Un HWANG
Soon Young Moon
Tae Young Ha
So Youn Kim
Hyuk Joon Choi
Myoung Hyun YOO
Jong Chan Lee
Young Seok Kim
Jae Keol Rhee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110025926A external-priority patent/KR20120108999A/ko
Priority claimed from KR1020120020455A external-priority patent/KR20120109297A/ko
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of WO2012128582A2 publication Critical patent/WO2012128582A2/fr
Publication of WO2012128582A3 publication Critical patent/WO2012128582A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne un composé inédit, ou un stéréo-isomère, ou un sel pharmaceutiquement acceptable de celui-ci et une composition pharmaceutique capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 (11β-HSD1) humaine en contenant. L'invention concerne un composé présentant une activité et une solubilité remarquables et pouvant être très efficacement formulé et administré, ainsi qu'une composition pharmaceutique capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine en contenant.
PCT/KR2012/002100 2011-03-23 2012-03-23 Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant Ceased WO2012128582A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR10-2011-0025926 2011-03-23
KR20110025920 2011-03-23
KR10-2011-0025920 2011-03-23
KR1020110025926A KR20120108999A (ko) 2011-03-23 2011-03-23 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물
KR1020120020455A KR20120109297A (ko) 2011-03-23 2012-02-28 인간 11-베타-히드록시스테로이드 탈수소효소 타입 1을 억제하는 화합물 및 이를 포함하는 약학조성물
KR10-2012-0020455 2012-02-28

Publications (2)

Publication Number Publication Date
WO2012128582A2 WO2012128582A2 (fr) 2012-09-27
WO2012128582A3 true WO2012128582A3 (fr) 2012-11-15

Family

ID=46879919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/002100 Ceased WO2012128582A2 (fr) 2011-03-23 2012-03-23 Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant

Country Status (1)

Country Link
WO (1) WO2012128582A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3057948B1 (fr) 2013-10-14 2018-03-14 Eisai R&D Management Co., Ltd. Dérivés de quinoléine substituée de manière sélective
MY192489A (en) 2013-10-14 2022-08-23 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
JP7093469B2 (ja) * 2018-10-17 2022-06-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ４－ピリジニルメチル－モルホリン誘導体および医薬としてのその使用
TW202035395A (zh) * 2018-10-17 2020-10-01 德商百靈佳殷格翰國際股份有限公司 4-嘧啶-5-基甲基-嗎啉衍生物及其作為藥物之用途
PE20211278A1 (es) * 2018-10-17 2021-07-19 Boehringer Ingelheim Int Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
US12398143B2 (en) 2019-06-04 2025-08-26 Boehringer Ingelheim International Gmbh Imidazopyrazine derivatives and the use thereof as medicament
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
CN114276280B (zh) * 2021-10-30 2023-10-31 苏州汉酶生物技术有限公司 一种手性苯丁胺醇磺酰胺类化合物的制备方法、制备其的中间体及制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154024A1 (en) * 2003-12-22 2005-07-14 Pfizer Inc Compounds useful in therapy
WO2006023844A2 (fr) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
WO2006077025A2 (fr) * 2005-01-18 2006-07-27 F. Hoffmann-La Roche Ag Morpholines en tant qu'agonistes de 5ht2c
JP2011016742A (ja) * 2009-07-07 2011-01-27 Astellas Pharma Inc 環状アミノ化合物又はその塩

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050154024A1 (en) * 2003-12-22 2005-07-14 Pfizer Inc Compounds useful in therapy
WO2006023844A2 (fr) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions et procedes comportant des antagonistes de recepteur active par la proteinase
JP2006131559A (ja) * 2004-11-05 2006-05-25 Takeda Chem Ind Ltd 含窒素複素環化合物
WO2006077025A2 (fr) * 2005-01-18 2006-07-27 F. Hoffmann-La Roche Ag Morpholines en tant qu'agonistes de 5ht2c
JP2011016742A (ja) * 2009-07-07 2011-01-27 Astellas Pharma Inc 環状アミノ化合物又はその塩

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE PUBCHEMCOMPOUND accession no. 3089177 *
DATABASE PUBCHEMCOMPOUND accession no. 3188324 *
DATABASE PUBCHEMCOMPOUND accession no. 3825918 *
DATABASE PUBCHEMCOMPOUND accession no. 564672 *
DATABASE PUBCHEMCOMPOUND accession no. 5651196 *
DATABASE PUBCHEMCOMPOUND accession no. 6243994 *
DATABASE PUBCHEMCOMPOUND accession no. 6737160 *
DATABASE PUBCHEMCOMPOUND accession no. 9417584 *
DATABASE PUBCHEMCOMPOUND retrieved from URL: http://pubchem.ncbi.nlm.nih.gov/search/search.cgi accession no. 1104591 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000477B2 (en) 2014-10-31 2018-06-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds
US10239870B2 (en) 2014-10-31 2019-03-26 Indivior Uk Limited Dopamine D3 receptor antagonists
US10654842B2 (en) 2014-10-31 2020-05-19 Indivior Uk Limited Dopamine D3 receptor antagonist compounds

Also Published As

Publication number Publication date
WO2012128582A2 (fr) 2012-09-27

Similar Documents

Publication Publication Date Title
WO2012128582A3 (fr) Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
IN2014KN00948A (fr)
EP4406950A3 (fr) Inhibiteur de lfa-1 et polymorphe de celui-ci
EP4219465A3 (fr) Inhibiteurs de prmt5 et leurs utilisations
WO2013091775A3 (fr) Utilisation de dérivés du cyclohéxanol comme principes actifs antimicrobiens
WO2012019426A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
MX354476B (es) Inhibidores de neprilisina.
MX2012007375A (es) 3-ceto-n-propargil 1-aminoindano.
WO2012021715A3 (fr) Formulations stables de linaclotide
MY183312A (en) Pharmaceutical formulation
WO2012019430A8 (fr) Dérivé de phtalazinone, son procédé de préparation et utilisation pharmaceutique
MY187718A (en) Pharmaceutical formulations
WO2012118308A3 (fr) Composition contenant un dérivé de pyrazole destinée à prévenir et à traiter les maladies cardiovasculaires
WO2011159124A3 (fr) Nouveau dérivé de benzoxazole présentant une activité inhibitrice contre l'interleukine 6, procédé pour le préparer, et composition pharmaceutique le contenant
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
HK1200314A1 (en) R(+)-n-methyl-propargyl-aminoindan
WO2013112959A8 (fr) Composés antifibrotiques et leurs utilisations
WO2012106665A3 (fr) Disialyllacto-n-tétraose (dslnt) ou variants, isomères, analogues et dérivés associés, pour prévenir ou inhiber une maladie intestinale
WO2013055687A3 (fr) R(+)-n-formyl-propargyl-aminoindane
WO2013093931A3 (fr) Nouveaux promédicaments de médicaments phénoliques
WO2012135615A3 (fr) Enopeptines, utilisations de celles-ci, et procédés de synthèse de celles-ci
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2013128379A3 (fr) Formes polymorphes cristallines de linagliptine
WO2013019091A3 (fr) Composé d'inhibition de la 11β-hydroxystéroïde déshydrogénase de type 1, et composition pharmaceutique le comprenant
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12760521

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12760521

Country of ref document: EP

Kind code of ref document: A2